SLXN Stock Analysis: Buy, Sell, or Hold?
SLXN - Silexion Therapeutics Corp Ordinary Shares
$0.36
-0.07 (-15.43%)
âŧ
5d:
+1.62%
30d:
-21.32%
90d:
-88.44%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When SLXN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SLXN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SLXN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SLXN is currently trading at $0.36, which is considered slightly low relative to its 30-day fair value range of $0.12 to $1.28.
Technical Outlook: Technically, SLXN is showing sideways momentum. Immediate support is located at $0.34, while resistance sits at $0.49. Short-term momentum is weak, with the stock down 15.4% recently.
Market Sentiment: SLXN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+16692.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SLXN is showing sideways momentum. Immediate support is located at $0.34, while resistance sits at $0.49. Short-term momentum is weak, with the stock down 15.4% recently.
Market Sentiment: SLXN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+16692.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.12 -
$1.28
Company Quality Score
43/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-15.4%)
- BULLISH: Trading 16692.6% below Wall St target ($60.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.12 -
$1.28
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.34
Resistance Level
$0.49
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.02
Wall Street Target
$60.00
(+16692.6%)
Share & Embed Analysis
Last updated: September 13, 2026 5:50 AM ET
Data refreshes hourly during market hours. Next update: 6:50 AM
Data refreshes hourly during market hours. Next update: 6:50 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLXN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
